✦ LIBER ✦

Papillary Thyroid Carcinoma: Factors Influencing Recurrence and Survival

✍ Scribed by Antonio Toniato; Isabella Boschin; Dario Casara; Renzo Mazzarotto; Domenico Rubello; Mariarosa Pelizzo

Book ID: 111772745
Publisher: Springer
Year: 2008
Tongue: English
Weight: 167 KB
Volume: 15
Category: Article
ISSN: 1068-9265
DOI: 10.1245/s10434-008-9859-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Papillary thyroid carcinoma in children:

Papillary thyroid carcinoma in children: risk factors and complications of disease recurrence

✍ Brian A. Palmer; Abdalla E. Zarroug; Rainer N. Poley; Joshua P. Kollars; Christo 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 92 KB

Medullary thyroid carcinoma: multivariat

Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival

✍ Isabel Peixoto Callejo; José Américo Brito; Carlos Manuel Zagalo; Jorge Rosa San 📂 Article 📅 2006 🏛 Springer Milan 🌐 Spanish ⚖ 623 KB

Retrospective Analysis of Predictive Fac

Retrospective Analysis of Predictive Factors for Recurrence After Curatively Resected Papillary Thyroid Carcinoma

✍ Katsuhiro Tanaka; Hiroshi Sonoo; Mai Hirono; Sumiko Ohkubo; Tsunehisa Nomura; Ma 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 154 KB

Preventable reoperations for persistent

Preventable reoperations for persistent and recurrent papillary thyroid carcinoma

✍ Maria A. Kouvaraki; Jeffrey E. Lee; Suzanne E. Shapiro; Steven I. Sherman; Dougl 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 112 KB

High Recurrent Rate of Multicentric Papi

High Recurrent Rate of Multicentric Papillary Thyroid Carcinoma

✍ Jen-Der Lin; Tzu-Chieh Chao; Chuen Hsueh; Sheng-Fong Kuo 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 259 KB

Advanced ovarian carcinoma. Factors infl

Advanced ovarian carcinoma. Factors influencing survival

✍ Baruch Klein; Geoffrey Falkson; C. F. Smit 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 402 KB

One hundred ten patients with advanced ovarian carcinoma (Stages IIIA, IIIB, and 1V) were evaluated for survival. They received as first treatment one of the following regimens: melphalan (L-PAM) (41 patients), cyclophosphamide plus methotrexate plus 5-fluorouracil (CMF) (16 patients), cyclophospham